‘Need a lie down': NSW parliamentary inquiry erupts over Labor's workers comp reforms
NSW's nominal insurer is 'plunging further into insolvency' by more than $6m a day the state's Treasurer has revealed, as Labor's controversial workers compensation reforms face another round of public inquiry.
Treasurer Daniel Mookhey revealed during an heated parliamentary inquiry on Tuesday that icare was tipped to rise from a deficit of $4.9bn at the end of 2024 to $6bn on July 1 absent reform.
'The nominal insurer is likely to hold $0.78 in assets for every dollar of future liability, meaning it is plunging further into insolvency at a faster rate,' Mr Mookhey said.
'Or, to put it even more simply, the scheme is no longer going backwards by $5m per day, it is going backwards by more than $6m every day.'
The state government's plan to reform workers compensation in NSW hit a major hurdle earlier this month when a strange coalition of the Liberals, Greens and the independents joined together to force another public inquiry.
The Liberals have proposed a number of amendments to the Bill, namely staying the lifting of the threshold of permanent whole person impairment (WPI) for psychological injury, and have called on the government to provide costings.
After hours of hearings, sparks immediately flew over modelling for the amendments between opposition treasury spokesman Damien Tudehope and Mr Mookhey who said 'the government is co-operating with this inquiry'.
Mr Mookhey and Mr Tudehope clashed again over the WPI, which Labor proposes lifting to 30 per cent. The Opposition claims doing so would harm workers injured psychologically to such an extent they may never work again.
NSW Treasury Secretary Michael Coutts-Trotter earlier told the committee there was a 'well developed pathway' for those people who, once completing their 130 weeks of payments, would instead transition to the NDIS scheme.
Labor claims the changes would not only help reduce the burden on the beleaguered state self-insurer, but would also allow injured workers access to lump sum payments should they wish, instead of remaining on compensation.
It was over the WPI that Mr Mookhey faced his second heated argument, this time with Greens MLC Abigail Boyd who asked if he knew the change 'would make us the harshest jurisdiction in Australia and one of the harshest in the world'.
Mr Mookhey said he didn't 'accept the characterisation'.
He claimed that at 130 weeks, 88 per cent of psychologically injured workers were back at work and accused Ms Boyd of being 'deliberately misleading' in claiming it would cut off '90 something per cent of people' currently on the scheme.
Consultant psychiatrist Dr Michael Epstein told the committee earlier on Tuesday afternoon that in comparison with other states, NSW's lifting of the WPI to 30 per cent would make it the 'harshest' in the country.
'NSW is going to take the crown,' Dr Epstein said.
Ms Boyd went on to summarise the evidence presented to the committee in three ways: she disputed the projected $2.5bn cost to the self-insurer, said there was 'no imminent danger of scheme collapse', and that the proposed WPI threshold was 'unbearably cruel'.
'I'll just make the point, you're entitled to vote against the legislation,' Mr Mookhey said in reply.
Ms Boyd went on to accused Mr Mookhey of using 'misleading language' in referring to payments made by the state government to the self-insurer as a 'bail out', and asked him to 'admit you were wrong'. In response, Mr Mookhey said: 'No'.
Following the heated exchange, Ms Boyd said: 'I think we need a bit of a lie down now'.
A range of practising psychiatrists, insurance industry representatives and leaders from NSW Treasury and the nominal insurer, icare, gave evidence during the hours-long hearing on Tuesday.
Mr Mookhey has warned the state self-insurer is tipped to cost the budget $2.6bn over the next five years, while premiums for the nominal insurer have already been set for eight-per-cent for the next financial year.
Exactly how the state government will deliver savings through the scheme was under the spotlight during the hearing, with leaders from NSW Treasury and the nominal insurer grilled over costings for the proposed amendments.
Largely, though, the numbers were not available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
37 minutes ago
- News.com.au
Audi Q4 Sportback review finds the perfect luxury EV salary sacrifice option
Salary workers would be salivating at the thought of four electrified rings. The new Audi Q4 makes the most of government incentives and could be in garages courtesy of novated leases for about $300 a week. With prices starting from less than $90,000, the Q4 is the least expensive e-tron we've seen from Audi. That also means it undercuts the Luxury Car Tax threshold so it's eligible for fringe benefit tax exemptions, which brings the leases into play and opens the door to a whole new market. Aptly named as it slots between the Q3 and Q5 in terms of size, the Q4 sits on the Volkswagen group's (that also owns Audi) modular electric drive platform, which has also been used for its Q5 sibling, the groovy VW ID Buzz, as well as the Cupra Born and Tavascan. The Q4 comes in SUV or Sportback body styles and two performance flavours, the 45 e-tron that just powers the front wheels, or the 55 e-tron that we tested and boasts all-wheel drive power – but also sees the cost push past $100,000. What do you get? Looking sleek and muscular in Sportback guise, the 21-inch alloys fill the expansive wheel arches, then on the inside it has a flat top and bottom steering wheel, stainless steel pedals and matt brushed aluminium inlays. Other nice kit includes three-zone aircon, electric tailgate with gesture control, 'S' embossed leather-trimmed seats, central 11.6-inch infotainment touchscreen, heated front seats, 10.25-inch driver instruments display and wireless phone mirroring apps. Our test car did have nearly $10,000 worth of extras courtesy of metallic paint ($1755), panoramic sunroof ($2925) and the $4700 Premium Plus package that incorporates tinted glass, 10-speaker Sonos stereo system, black exterior styling pack and exterior mirrors, along with an augmented reality head-up display. Grey is the only solid colour that doesn't attract a $1755 premium, with black, two shades of blue, violet, silver, another grey hue and white all metallic options. The Q4 has been available overseas for a few years but the latest models now available Down Under can charge quicker than the initial offerings – using a 175kW public charger the Q4 can shift from 10 to 80 per cent in about 28 minutes. Three-phase 11kW home chargers can replenish the battery in about 12 hours. Running costs are among the best you'll find in the prestige realm. The prepaid deal of $1900 covers three services with intervals every two years or 30,000km. It also comes with six years of roadside assist. All Audi e-trons come with a year's free subscription for the Chargefox network. How was the drive? Cornering flat and feeling nimble, despite tipping the scales at 2235kg, the Q4 offers composure and fuss-free driving. Riding on the massive 21-inch alloys it feels harsh ruts and potholes, yet maintains surprising composure under the majority of circumstances. Quicker than the front-wheel drive versions, the Quattro models manage the 0-100km/h sprint in 5.4 seconds. That's reasonably quick – but not insanely fast like some EVs. The steering feels light and lacks road feel when the going gets twisty. It rekindled memories of Audis from the early 2000s. Cabin serenity is assured and it boasts impressive boot space that easily swallowed our weekly family grocery shop of about 10 bags, while the door-top bottle holders are brilliant – it's a new benchmark and will be loved by those who like their H2O within close reach. Audi claims average consumption of just under 18kWh/100km, but we only got close to that on an easy highway journey. Our test saw an average of 21.6kWh/100km Would you buy one? Kel: For some reason I didn't gel with the Q4, which is unusual for Audis and my preferences. Great looks and easy to drive, it was nice but wasn't remarkable. We recently drove the SQ6 e-tron which was more expensive but I could see and feel the technology advancements. I could happily live with a Q4, but I'd want more value before becoming an owner. Grant: While we drove the 55 all-wheel drive derivative, it would be hard to pass up the benefits of the cheaper 45 models. Leasing benefits offer the best bang for buck when it comes to the Q4, which is a great family runabout EV. For those who want badge kudos, it's a predictable drive with anxiety free-range.
ABC News
an hour ago
- ABC News
The new financial year is here and with it comes several law changes. Here's what to know
The new financial year is here and with it comes new laws, rules and payments that will effect Australian families and businesses. Here's a breakdown of all the changes coming your way from July 1. There are several changes to Australian road rules that will come into effect on the first day of July. Nationally, AI-powered surveillance cameras will be rolled out across the country to detect use of phones while driving. There will also be new speed limits for many states in response to increased road deaths. In Queensland, there will be a 3.4 per cent increase in car registration and fines. In New South Wales, drivers will face higher penalties if they fail to wear a seatbelt. In Victoria, drivers will be required to slow down to 40 kilometres per hour when approaching or passing by a slow-moving (less than 10 kilometres an hour) or stationary police, emergency or escort vehicle. Failure to comply will result in a maximum fine of $961. In Western Australia, speed limits on several roads will be significantly reduced in response to the state's road toll. You can see what roads here. South Australian drivers will be forced to slow down to 25kph when passing breakdown recovery vehicles. Failure to slow down could result in fines of up to $1,648. From the first of July, the minimum wage will go up by 3.5 per cent. Millions of Australian workers will get a 3.5 per cent pay rise from July 1, following the Fair Work Commission's (FWC) annual review of the minimum wage and award agreements. The commission's decision increases the national minimum wage to $24.95 per hour or $948 per week, based on a full-time, 38-hour working week. The amount of parental leave pay available to families will increase to 120 days (24 weeks) for children born or adopted from July 1, 2025. This will increase to 24 weeks for children born or adopted after July 1 next year, and to 26 weeks in 2026. It's estimated about 180,000 families receive the support each year. The following will also increase: The number of days you get is based on the date your child is born or comes into your care. If you submit a pre-birth claim before July, your parental leave pay days balance will be 110 days. If your child is adopted from July 1 2025, the government will add an extra 10 days once it receives document proof of the adoption or birth. There are a couple of changes coming for superannuation on July 1. The guarantee rate which is the percentage of a salary an employer must pay to their employees' superannuation account — will increase from 11.5 to 12 per cent. The minimum SG rate employers must pay for each eligible employee from July 1, 2024 is 11.5 per cent of their ordinary time earnings (OTE). This is scheduled to progressively increase to 12 per cent on July 1, 2025. In three states, power prices are set to go up. The Australian Energy Regulator (AER) will raise power prices for many people in New South Wales, South Australia and South East Queensland. It announced what's called a Default Market Offer for the next financial year. Changes in pricing will depend on where you live and you can check what that will be here. It will depend on which state you're in, which power company you go with and what plan you're on. So we can't give a definitive answer on that — but, by looking at the DMO figures, we can give you a general idea for the three states covered by the AER. For more information, click here. From July, the rate of the age pension for asset-tested couples will increase by $34.50 a fortnight, and $22.50 a fortnight for singles. The National Disability Insurance Agency (NDIA) will introduce changes to NDIS pricing from July 1, 2025 designed to ensure NDIS participants are charged in line with other Australians receiving these supports through Medicare or Private Health Insurance. Each year, the agency said it undertakes an annual pricing review (APR) to ensure the market is delivering sustainable and high-quality supports for NDIS participants. As a result of the review there will be cuts to allied health services as well as a reduction of claimable travel time by 50 per cent. There has been criticism by advocacy groups who say it will make access to services more difficult in rural areas.
News.com.au
an hour ago
- News.com.au
Health Check: Tetratherix breaks biotech IPO drought with 13pc gain on debut
Tetratherix's listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today's ASX debut of wound management house Tetratherix (TTX) has raised the hopes of other life-science plays that have eyed an IPO but have relegated the idea to the too-hard basket. Having downsized its offer from $35 million $25 million to banish the fast money, Tetratherix traded up to 13% above their $2.88 a share offer price. The company has developed an injected liquid polymer that hardens at body temperature and then biodegrades after the job is done. Yet to be approved, the platform-based tech targets novel applications including tissue healing, bone regeneration and surgical spacing (such as in prostate radiation therapy). CEO Will Knox dubs the platform as 'medical Lego', in that the products are built from the same polymer structure. 'That means you can use the same underlying biological performance and safety data in all regulatory applications. 'Our path to market is a lot faster and simpler because the data is interchangeable across the different applications.' Post raising, Tetratherix has cash of circa $30 million. This factors in two US Food & Drug Administration (FDA) approval applications, one further submission and 'multiple clinical trial readouts'. Tetratherix is the first life sciences IPO since late November 2024, when cryogenics play Vitrafy Life Sciences (ASX:VFY) and nerve repair house ReNerve (ASX:RNV) listed on the same day. Their shares are down 20% and 50% to date, respectively. Aptium is on IPO foot-ing The developer of an AI-powered tool for the podiatry market, the private Aptium is eyeing an IPO after a private whip-'round. Aptium's scanner provides real-time thermal and three and four dimensional analysis of motion and the shape of the foot. This enables 3D manufacturing of patient-specific insoles 'with precision-grade firmness and softness:. The tech also may detect diabetic foot ulcers early. Co-founded by biotech greybeards Dr Mel Bridges and Carl Stubbings, Aptium is seeking to tap $5 million in a private convertible note round. The company aspires to list within the next 18 months or so. Bridges has founded six companies, including ImpediMed (ASX:IPD) and the formerly ASX-listed Panbio. Stubbings was former CEO of Sienna Cancer Diagnostics, which merged with Bard1 to become Inoviq (ASX:IIQ). Aptium could test IPO appetite in more ways than one. That's because the company is 40% owned by Greg Creed, the former CEO of US giant Yum! Brands which owns KFC, Pizza Hut and Taco Bell. Dimerix pockets first milestone from Japanese partner Kidney drug developer Dimerix (ASX:DXB) has pocketed $4.2 million as its first milestone payment from Japan's Fuso, one of the company's four global partners. Signed in January this year, the Fuso compact could deliver up to $100 million of milestone payments. This is subject to progress on Dimerix's lead phase III program, for the kidney ailment focal segmental glomerulosclerosis. In October 2023 Dimerix inked distribution deals with the London-based Advanz Pharma (covering Europe, Canada, Australia and New Zealand). The company followed up in May last year by entering a Middle East licensing agreement with the Oman-based pharma group, Taiba. In its biggest deal, Dimerix last May signed up the Nasdaq-listed rare diseases house Amicus Therapeutics for the US honours. Collectively, the deals promise $1.4 billion of potential milestones, largely contingent on eventual FDA drug approval. The Amicus deal alone involves of US$520 million of success-based payments. The Fuso milestone became payable on opening of the first Japanese site for the Action 3 trial. Investors now expect likely follow-on deals in territories including China, Latin America and South Korea. LTR Pharma is full bottle on safety study Drug development is all about getting the small stuff right, such as whether the packaging is tickety-boo. In this vein, LTR Pharma (ASX:LTP) has affirmed that the bottle and pump components for its proposed nasal mist based erectile dysfunctional treatment meet accepted standards. LTR completed the so-called extractables study with co-development partner Aptar Pharma. The study confirmed that all detected compounds met International Council for Harmonisation safety thresholds – the standard adopted by the FDA and other agencies. A 'leachables' study is now underway, to support an FDA marketing submission. As the name suggests, the leachables study evaluates the potential migration of compounds from packaging into the liquid. This takes account of 'real-world' storage conditions, such as the back of the bedside drawer. The study will run for at least 24 months, after which the company can submit its FDA entreaty. Dubbed Spontan, LTR's treatment is based on the same active ingredient as current oral treatments but is much faster acting. LTR is also developing Oroflow, a spray treatment for a group of ailments that affect swallowing function. Orthocell hits the right nerve Nerve repair play Orthocell (ASX:OCC) reports the first use of its Remplir device in a US surgical procedure, to repair a foot injury. The FDA approved Remplir in April. The company says the first use is a crucial step in its US rollout, 'building surgical experience and knowledge of the product that will be key in driving product sales'. Remplir is a collagen 'wrap' that improves regeneration of damaged nerves and requires less stitching. The surgery took place at an unnamed Ohio hospital, sourced from Orthocell's network of 14 specialist distributors. These intermediaries have 'mature, direct-to-surgeon, hospital and other customer relationships' across 25 US states. Orthocell CEO Paul Anderson said the critical first step in the US rollout was 'getting Remplir into surgeons' hands for them to gain familiarity with its key features and benefits in clinical practice'. The company promises 'material' sales growth in the December half - which of course starts tomorrow – with the financial benefits reflected in the June half 2026 accounts. Orthocell estimates that surgeons carry out two million peripheral nerve repairs annually, equating to a US$3.5 billion market. This is across its approved markets of Australia/New Zealand, Singapore, the US, Europe/UK, Canada, Brazil, Japan, Hong Kong and Thailand.
